News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
92,781 Results
Type
Article (6743)
Company Profile (39)
Press Release (85999)
Section
Business (27723)
Career Advice (127)
Deals (3992)
Drug Delivery (32)
Drug Development (14128)
Employer Resources (12)
FDA (2852)
Job Trends (2111)
News (49219)
Policy (6007)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
2026 Pharm Country Premier (1)
Academia (426)
Accelerated approval (2)
Adcomms (7)
Allergies (30)
Alliances (9000)
ALS (13)
Alzheimer's disease (261)
Antibody-drug conjugate (ADC) (39)
Approvals (2855)
Artificial intelligence (39)
Autoimmune disease (8)
Automation (3)
Bankruptcy (19)
Best Places to Work (1797)
BIOSECURE Act (16)
Biosimilars (74)
Biotechnology (26)
Bladder cancer (20)
Brain cancer (6)
Breast cancer (51)
Cancer (438)
Cardiovascular disease (20)
Career advice (110)
Career pathing (3)
CAR-T (20)
Cell therapy (83)
Cervical cancer (3)
Clinical research (11518)
Collaboration (183)
Compensation (41)
Complete response letters (9)
COVID-19 (546)
CRISPR (5)
C-suite (48)
Cystic fibrosis (13)
Data (418)
Denatured (2)
Depression (5)
Diabetes (35)
Diagnostics (559)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (23)
Drug pricing (22)
Drug shortages (1)
Duchenne muscular dystrophy (25)
Earnings (9476)
Editorial (5)
Employer branding (3)
Employer resources (10)
Events (11812)
Executive appointments (114)
FDA (3180)
Featured Employer (9)
Frontotemporal dementia (1)
Funding (141)
Gene editing (24)
Generative AI (5)
Gene therapy (79)
GLP-1 (107)
Government (1308)
Grass and pollen (1)
Guidances (11)
Healthcare (1956)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (37)
Indications (8)
Infectious disease (579)
Inflammatory bowel disease (46)
Inflation Reduction Act (4)
Influenza (15)
Intellectual property (11)
Interviews (11)
IPO (1836)
IRA (13)
Job creations (385)
Job search strategy (107)
Kidney cancer (2)
Labor market (2)
Layoffs (55)
Legal (557)
Liver cancer (13)
Lung cancer (73)
Lymphoma (25)
Management (2)
Manufacturing (99)
MASH (10)
Medical device (1167)
Medtech (1168)
Mergers & acquisitions (2247)
Metabolic disorders (82)
Multiple sclerosis (16)
NASH (2)
Neurodegenerative disease (18)
Neuropsychiatric disorders (1)
Neuroscience (333)
NextGen: Class of 2025 (697)
Non-profit (348)
Northern California (466)
Now hiring (10)
Obesity (30)
Opinion (45)
Ovarian cancer (20)
Pain (8)
Pancreatic cancer (13)
Parkinson's disease (9)
Partnered (3)
Patents (29)
Patient recruitment (19)
Peanut (21)
People (7980)
Pharmaceutical (11)
Pharmacy benefit managers (2)
Phase I (3793)
Phase II (4793)
Phase III (4227)
Pipeline (282)
Podcasts (6)
Policy (40)
Postmarket research (297)
Preclinical (1475)
Press Release (66)
Prostate cancer (16)
Psychedelics (5)
Radiopharmaceuticals (36)
Rare diseases (69)
Real estate (915)
Recruiting (4)
Regulatory (4766)
Reports (11)
Research institute (388)
Resumes & cover letters (11)
RNA editing (1)
RSV (10)
Schizophrenia (11)
Series A (33)
Series B (13)
Service/supplier (3)
Sickle cell disease (7)
Southern California (469)
Special edition (3)
Spinal muscular atrophy (21)
Sponsored (9)
Startups (574)
State (1)
Stomach cancer (3)
Supply chain (9)
Tariffs (2)
The Weekly (4)
United States (3998)
Vaccines (183)
Venture capitalists (4)
Webinars (1)
Weight loss (14)
Women's health (3)
Date
Today (21)
Last 7 days (131)
Last 30 days (534)
Last 365 days (6351)
2025 (1657)
2024 (6510)
2023 (6966)
2022 (9060)
2021 (9473)
2020 (8175)
2019 (5843)
2018 (4511)
2017 (5056)
2016 (4617)
2015 (5268)
2014 (3717)
2013 (2892)
2012 (2984)
2011 (3146)
2010 (2572)
Location
Africa (92)
Alabama (11)
Alaska (1)
Arizona (12)
Arkansas (2)
Asia (7496)
Australia (882)
California (1102)
Canada (228)
China (167)
Colorado (32)
Connecticut (25)
Delaware (37)
Europe (13840)
Florida (128)
Georgia (18)
Idaho (13)
Illinois (45)
India (11)
Indiana (39)
Iowa (1)
Japan (27)
Kansas (3)
Kentucky (9)
Louisiana (2)
Maine (5)
Maryland (313)
Massachusetts (757)
Michigan (23)
Minnesota (44)
Mississippi (1)
Missouri (14)
Montana (5)
Nebraska (1)
Nevada (4)
New Hampshire (3)
New Jersey (438)
New Mexico (4)
New York (307)
North Carolina (193)
North Dakota (7)
Northern California (466)
Ohio (39)
Oklahoma (7)
Oregon (2)
Pennsylvania (185)
Puerto Rico (1)
Rhode Island (5)
South America (134)
South Carolina (2)
Southern California (469)
Tennessee (3)
Texas (143)
Utah (24)
Virginia (16)
Washington D.C. (6)
Washington State (87)
Wisconsin (7)
92,781 Results for "cytovance biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs
January 13, 2025
·
1 min read
Business
ExcellGene SA and Cytovance Biologics Join Forces to Transform Large Molecule Biologics Development and Manufacture
ExcellGene SA proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization based in the USA.
May 8, 2024
·
3 min read
Press Releases
Cytovation Appoints Martin Dewhurst to its Board of Directors
February 13, 2025
·
2 min read
Cytovance Biologics and Alcami Unite to Deliver End-to-End Solutions for Biologics Developers
Cytovance Biologics has announced a strategic collaboration with fellow CDMO Alcami Corporation to expand its large molecule biologic manufacturing and sterile fill finish offering.
December 11, 2023
·
3 min read
Press Releases
Cancer Research UK, Cytovation and the Norwegian Cancer Society collaborate to advance treatment for rare cancer
January 23, 2025
·
5 min read
Cytovance Biologics Announces Dr. Axel Schleyer to Expand Footprint and Service Offering as Chief Commercial Officer
Cytovance Biologics, a leading full-service mammalian and microbial large molecule contract development and manufacturing organization (CDMO), announced today the addition of Axel Schleyer, Ph.D., MBA,
September 26, 2023
·
2 min read
Large Molecule CDMO, Cytovance Biologics, and Custom Strain Development Expert, Vectron Biosolutions, Partner to Improve Development of Complex Microbial Molecules
Cytovance Biologics announced a strategic, international collaboration with Vectron Biosolutions to add customized E. coli strain development to the CDMO’s microbial program.
October 10, 2023
·
5 min read
Business
Cytovance Biologics Announces Ping Zhang as Chief Executive Officer
Cytovance® Biologics announces the appointment of Mr. Ping Zhang as Chief Executive Officer.
January 16, 2023
·
2 min read
Business
Cytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial Biomanufacturing
Cytovance Biologics, Inc. and Phenotypeca Limited have entered into an agreement to provide optimized Saccharomyces cerevisiae strains for biopharmaceutical manufacturing.
March 11, 2023
·
3 min read
Business
Cytovation Announces Appointment of Ellen Lubman, MBA to its Board of Directors
Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, announced the election of Ellen Lubman, MBA, to its Board of Directors.
December 20, 2023
·
3 min read
1 of 9,279
Next
